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Key Points 30 
Question  Can machine learning be used to predict future incidence of Alzheimer’s disease 31 
using electronic health records?  32 
 33 
Findings  We developed and validated supervised machine learning models using the EHR 34 
data from 40,736 South Korean elders (age above 65 years old). Our model showed acceptable 35 
accuracy in predicting up to four year subsequent incidence of AD.  36 
 37 
Meaning  This study shows the potential utility of the administrative EHR data in predicting risk 38 
for AD using data-driven machine learning to support physicians at the point of care.  39 
40 





Background: Prediction of future incidence of Alzheimer’s disease may facilitate intervention 42 
strategy to delay disease onset. Existing AD risk prediction models require collection of 43 
biospecimen (genetic, CSF, or blood samples), cognitive testing, or brain imaging. Conversely, 44 
EHR provides an opportunity to build a completely automated risk prediction model based on 45 
individuals’ history of health and healthcare. We tested machine learning models to predict 46 
future incidence of AD using administrative EHR in individuals aged 65 or older.  47 
Methods: We obtained de-identified EHR from Korean elders age above 65 years old 48 
(N=40,736) collected between 2002 and 2012 in the Korean National Health Insurance Service 49 
database system. Consisting of Participant Insurance Eligibility database, Healthcare Utilization 50 
database, and Health Screening database, this EHR contain 4,894 unique clinical features 51 
including ICD-9/10 codes, medication codes, laboratory values, history of personal and family 52 
illness, and socio-demographics. Our event of interest was new incidence of AD defined from 53 
the EHR based on both AD codes and prescription of anti-dementia medication. Two definitions 54 
were considered: a more stringent one requiring a diagnosis and dementia medication resulting 55 
in n=614 cases (“definite AD”) and a more liberal one requiring only diagnostic codes (n=2,026; 56 
“probable AD”). We trained and validated a random forest, support vector machine, and logistic 57 
regression to predict incident AD in 1,2,3, and 4 subsequent years using the EHR available 58 
since 2002. The length of the EHR used in the models ranged from 1,571 to 2,239 days. Data 59 
was randomly split into training (60%), validation (20%), and test sets (20%) so that AUC values 60 
represent true out of sample prediction are based on the test set. 61 
Results:  Average duration of EHR was 1,936 days in AD and 2,694 days in controls. For 62 
predicting future incidence of AD using the “definite AD” outcome, the machine learning models 63 
showed the best performance in 1 year prediction with AUC of 0.781; in 2 year, 0.739; in 3 year, 64 




0.686; in 4 year, 0.662. Using “probable AD” outcome, the machine learning models showed the 65 
best performance in 1 year prediction with AUC of 0.730; in 2 year, 0.645; in 3 year, 0.575; in 4 66 
year, 0.602. Important clinical features selected in logistic regression included hemoglobin level 67 
(b=-0.902), age (b=0.689), urine protein level (b=0.303), prescription of Lodopin (antipsychotic 68 
drug) (b=0.303), and prescription of Nicametate Citrate (vasodilator) (b=-0.297).  69 
Conclusion: This study demonstrates that EHR can i detect risk for incident AD. This approach  70 
could enable risk-specific stratification of elders  for better targeted clinical trials.      71 





Screening individuals at risk for Alzheimer’s disease (AD) based on medical health records in 73 
preclinical stages may lead to more widespread early detection of AD pathology and ultimately 74 
to better therapeutic strategies for  delaying the onset of AD 1-3. In contrast to biomarkers 75 
requiring the collection of bio-specimen (e.g., serum or fluid) or imaging data, electronic health 76 
records (EHR) does not require additional time or effort for data collection. Furthermore, with 77 
advent of digitalization, the amounts of the EHR available for predictive modeling have 78 
exponentially increased. Because it is ubiquitous and affordable, developing risk prediction of 79 
AD using the EHR will have a great impact on the AD research and clinical care. However, 80 
despite of the tremendous potential value of EHR-based predictive models, little is known about 81 
the utility of such models for AD screening.  82 
 83 
For population AD screening, prior models are based on predefined features including health 84 
profiles, such as sociodemographic (age, sex, education), lifestyle (physical activity), midlife 85 
health risk factors (systolic blood pressure, BMI and total cholesterol level)4,5; and cognitive 86 
profiles6,7. Despite of the demonstrated accuracy of these models, an important outstanding 87 
question is whether the several curated variables may sufficiently account for the 88 
heterogeneous etiology of multi-factorial AD. Indeed, a meta-analysis study shows that multi-89 
factor models best predict risk for dementia, whereas single-factor models do poorly5, 90 
suggesting accurate AD screening with practical utility in large populations require sufficiently 91 
large feature space. An important new approach for developing individualized predictive 92 
modeling is the use of the rigorous data-driven machine learning that can harvest salient 93 
information from large-scale EHR to make an individual-specific predictions. 94 
 95 




Machine learning is an optimal choice of the analytic method for analyzing large-scale EHR 96 
containing thousands of descriptors in hundreds of thousands of individuals. Studies show 97 
successful application of machine learning to the EHR in predicting incident diseases (cancer, 98 
diabetes, schizophrenia, etc) or mortality8-11. Given the recent rapid growth of the machine 99 
learning technology, application of the AI technology to clinical predictive modeling is likely to 100 
have a deep impact on medicine12. But to our knowledge data-driven predictive modeling with 101 
EHR data has not been previously used to predict incident AD.  102 
 103 
When developing machine learning models, it is important to use sufficiently large data 104 
representative of a target population of interest. The size and breadth of the data is important for 105 
model precision, while the representativeness of the data is important for minimizing potential 106 
bias an improving generalizability. In the present study, we use a large nationally representative 107 
(South Korea) sample cohort taken from the Korean National Health Insurance Service EHR 108 
database. We construct and validate data-driven machine learning models to predict future 109 
incidence of AD using the extensive measures collected within the EHR.  We demonstrate the 110 
feasibility of developing accurate prediction models for AD which may then provide a starting 111 
point for future 112 
113 




Materials and Methods 114 
Datasets 115 
We used the National Health Insurance Service (NHIS)-National Elderly cohort Database, a 116 
subsample of the National Health Insurance Service-national sample cohort13. This database 117 
contains for each individual features of services/diagnoses/prescriptions associated with all the 118 
health care services provided by the NHIS. All EHR was binned monthly. Clinical features 119 
include demographics and socioeconomics from the Participant Insurance Eligibility database; 120 
disease and medication codes from the Healthcare Utilization database; and laboratory values, 121 
health profiles, and history of personal and family illness from the National Health Screening 122 
database (from bi-annual health check-up required for elders with age above 40). The database 123 
consists of a 10% sample of randomly selected elderly individuals (430,133 individuals) over 65 124 
years of age containing health and insurance billing data of from 2002 to 2012 in South Korea. 125 
Individuals who died between 2002 and 2012 were not included in this cohort. This database is 126 
representative of the Korean population because for the years investigated in this study, the 127 
Korean NHIS covered over 96% of the entire 50-million South Korean population; thus, presents 128 
minimal selection bias (Supplemental Figure 1). 129 
 130 
Of those samples, 40,736 elders were selected in this study, whose records exist in all the three 131 
databases (Participant Insurance Eligibility database, Healthcare Utilization database, and 132 
National Health Screening database). The Korean NHIS Electronic Health Records Detailed 133 
description of the EHR including access is available elsewhere 134 
(https://nhiss.nhis.or.kr/bd/ab/bdaba000eng.do). Ethics review and institutional review boards 135 
approved the study with exemption of informed consent (for retrospective, de-identified, publicly 136 
available data) (IRB number NHIMC 2018-12-006).    137 
 138 




Definition of AD 139 
Incident AD was the outcome variable. We used the two criteria to define AD: ICD-10 codes of 140 
AD14 (F00, F00.0, F00.1, F00.2, F00.9, G30, G30.0, G30.1, G30.8, G30.9) and dementia 141 
medication prescribed with an initial AD diagnosis (e.g., donepezil, rivastigmine, galantamine, 142 
and memantine). When both criteria were used, we labeled it as definite AD. We also 143 
considered a broader definition of AD using only ICD-10 codes to minimize false negative cases 144 
(e.g. individuals with AD diagnose who did not take medication); this was labeled as probable 145 
AD. Within each individual with AD incidence, the EHR after the AD incidence was excluded. 146 
We conducted predictive modeling using both outcome variables.  147 
 148 
Data and Preprocessing 149 
We used the following variables from the EHR data: 21 features including laboratory values, 150 
health profiles, history of personal and family illness from the Health Screening database; three 151 
features including age, sex, income level from the Participant Insurance Eligibility database; and 152 
the 4,871 features including ICD 9/10 codes and medication codes. Descriptions of data coding 153 
and exclusion criteria for all the features except for ICD 9/10 codes and medication codes are 154 
available in Supplementary Table 1. 155 
 156 
Our data preprocessing steps are as follows. (i) EHR alignment: We aligned the EHRs to each 157 
individual’s initial AD diagnosis (event-centric ordering29). (ii) ICD 9/10 and medication coding: 158 
Since ICD9/10 and medication codes have hierarchical structures, we used the first disease 159 
category codes (e.g., F00 [Dementia in Alzheimer’s disease] including F00.0 [Dementia in 160 
Alzheimer’s disease with early onset], F00.1 [Dementia in Alzheimer’s disease with late onset], 161 
F00.2 [Dementia in Alzheimer’s disease, atypical or mixed type], and F00.9 [Dementia in 162 
Alzheimer´s disease, unspecified]), and the first 4 characters for the medication codes 163 
representing main ingredients. (iii) Rare disease or medication codes found less than five times 164 




in the entire data were excluded from the analysis (1,179 disease and 362 medication codes). 165 
(iv) if a participant has no health screening data (laboratory values, health profiles, and history of 166 
personal and family illness from the National Health Screening database) during the last two 167 
years of the processed data (in Korea an biannual health screening is required for every elder), 168 
we excluded that participant from the analysis. After preprocessing, we identified 4,894 unique 169 
variables used in the models (see Table 3 for detailed information).      170 
 171 
For each n-year prediction, within the AD group, we used the EHR between 2002 and the year 172 
of incident AD – n because it requires at least n years prior to the incident AD. Within the non-173 
AD group, we used the EHR from 2002 to 2010 – n. For example, for 1 year prediction, if a 174 
patient was diagnosed with AD at 2009, we used the EHR between 2002 and 2008; for 2 year 175 
prediction, 2002-2007; for 3 year, 2002-2006; and for 4 year, 2002-2005.  176 
 177 
Machine learning analysis 178 
We implemented three machine learning algorithms: random forest, support vector machine 179 
with linear kernel, and logistic regression. Data was randomly split into training (60%), validation 180 
(20%), and test sets (20%) in a stratified manner. Feature selection was done within train sets 181 
using the variance threshold method15. Hyper-parameters optimization was done within 182 
validation sets. The following parameters were tuned: for random forest, the minimum number 183 
of samples required at a leaf node and the number of trees in the forest; for support vector 184 
machine, regularization strength; for logistic regression, the inverse of regularization strength. In 185 
logistic regression L2 regularization was used. Generalizability of model performance was 186 
assessed on the test sets. We measured the following model performance metrics in the test 187 
set: The area under the receiver operating characteristic curve (ROC), sensitivity and specificity. 188 
We comply with the Transparent Reporting of a Multivariable Prediction Model for Individual 189 




Prognosis or Diagnosis (TRIPOD) reporting guideline. Codes are available at 190 
https://github.com/a011095/koreanEHR. 191 
192 




Results  193 
Sample characteristics  194 
Of 40,736 individuals with age above 65 years in 2002, we identified 614 unique individuals with 195 
AD incidence using the definite AD outcome, 2,026 with AD incidence using the probable AD 196 
definition, and 38,710 elders with no AD incidence. The rate of AD in this cohort was 1.56% 197 
using the definite AD definition, and 4.97% using the probable AD definition. Demographic 198 
characteristics showed significant differences in age between both AD groups and non-AD 199 
groups and non-significant differences in income and sex (Table 1).  200 
 201 
Model prediction 202 
Classifiers were trained on these to predict 0,1,2,3, and 4 subsequent-year incidence of AD. 203 
When using the definite AD definition (based on ICD-10 codes and dementia prescription), in 204 
predicting 0yr incidence of AD, random forest (RF) showed the best performance with AUC of 205 
0.887 (Table 2 and Figure 2). When using the probable AD definition (based on ICD-10 codes), 206 
classification performance was slightly lower with AUC of 0.805 (RF). Classification 207 
performance decreased in predicting future incident AD of later years: using the definite AD 208 
definition, AUC of 0.781 (1 year), 0.739 (2 year), 0.686 (3 year), and 0.662 (4 year); using the 209 
probable AD definition, AUC of 0.730 (1 year), 0.645 (2 year), 0.575 (3 year), and 0.602 (4 210 
year). Numbers of features and look-back periods also decreased in later year (Table 3).  211 
 212 
Important features 213 
Logistic regression identified the features positively related to incident AD. These included age 214 
(b value = 0.689), elevated urine protein (0.303), prescription of Zotepine (antipsychotic drug) 215 
(0.303), and the features negatively related to incident AD, such as, decreased hemoglobin (-216 




0.902), prescription of Nicametate Citrate (-0.297), diagnosis of other degenerative disorders of 217 
nervous systems (-0.292), and disorders of the external ear (-0.292) (Table 4). 218 
219 





This study assessed the utility of the EHR in predicting the future incidence of AD. Using 221 
machine learning, we predicted future incidence of AD with acceptable accuracy in terms of 222 
AUC (0.781 in one-year prediction). The high accuracy of our models based on large nation-223 
wide samples may lend a support to the potential utility of the EHR-based predictive modeling in 224 
AD. Despite of the limitations inherent to the use of administrative EHR, such as the inability to 225 
directly ascertain clinical phenotypes, this study demonstrates the potential utility of the EHR for 226 
AD screening, when combined with rigorous data-driven machine learning.  227 
 228 
Our model performance with AUC of 0.89, 0.78, and 0.66 in predicting baseline, subsequent 229 
one-year, and four-year incident AD is relatively accurate compared with the literature. In all-230 
cause dementia risk prediction based on genetic (ApoE) or neuropsychological evaluations, 231 
MRI, health indices (diabetes, hypertension, lifestyle), and demographic (age, sex, education) 232 
variables, prior models show accuracy ranging from 0.5 to 0.78 in AUC (reviewed in 16). Of note, 233 
compared with these studies, our approach is solely based on administrative EHR without 234 
neuropsychological, genetic testing, or brain imaging. This has important implications for the 235 
practical utility of the EHR-based risk prediction, in that it can provide an early indication of AD 236 
risk to clinicians. Together with existing screening tools (e.g., MMSE), this mayassist deciding 237 
when to seek  a further clinical assessment to a given patient in an individual-specific manner. 238 
 239 
Our model detected interesting EHR-based features associated with incident AD. The data-240 
driven selection of features is consistent with risk factors found in the literature.  A decrease in 241 
hemoglobin level was selected as the feature  most stronglyassociated with incident AD. 242 
Indeed, anemia is known as an important risk factor for dementia17-19. A study using National 243 
Health Insurance Service-National Health Screening Cohort (NHIS-HEALS), the NHIS health 244 




screening data in Korea, not only found that anemia was associated with dementia, but also 245 
revealed a dose-dependent relationship between anemia and dementia20. Likewise, our data-246 
driven model shows the hemoglobin level as the most significant predictor. This finding has 247 
implications for public health because anemia is a modifiable factor. Given our finding and the 248 
consistent literature on the large association between hemoglobin level and AD and other 249 
dementia, future research may investigate the biological pathway of anemia’s contribution to AD 250 
pathology and cognitive decline. 251 
 252 
We also noted a positive association between urine protein level and incident AD. In the EHR, 253 
protein in urine is typically measured using urine dip stick. This approach is not a quantitative 254 
measure of urine protein, but it is useful as a screening method for proteinuria 21,22. Literature 255 
shows association between albuminuria and dementia23. Our finding suggests the potential 256 
utility of a urine test as part of the routine health check-up in AD risk prediction.  257 
 258 
Four medications were also associated with incident dementia within top ten features. We found 259 
that Zotepine, Eperisone hydrochloride had a positive association and Nicametate Citrate and 260 
Tolfenamic acid had a negative association with incident AD. It is interesting that patients 261 
prescribed  tolfenamic acid showed lower incidence of AD. This drug used in Korea for pain 262 
control in conditionsr such as rheumatoid arthritis. It is known to lower the gene expression of 263 
Amyloid precursor protein 1(APP1) and beta-site APP cleaving enzyme 1(BACE1) by promoting 264 
the degradation of specificity protein 1(Sp1)24-26. As a potential modifier of tau protein, 265 
Tolfenamic acid is under investigation as a potential drug to prevent and modify the progression 266 
of AD27. The results of this study support the above experimental result and show that 267 
tolfenamic acid may be a potential anti-dementia medication.  268 
 269 




Zotepine is an atypical antipsychotic drug with proven efficacy for treatment of schizophrenia. 270 
Our model showed the use of zotepine positively correlated with incident AD. There are two 271 
possible interpretations. Some studies indicate that individuals with schizophrenia may have an 272 
increased risk for the development of dementia28. It is possible that the incident AD was high in 273 
patients with schizophrenia using zotepine. Alternatively, zotepine may have been used to 274 
control behavioral and psychological symptoms before incident AD29. Further research is 275 
required to address why other schizophrenia drugs or other drugs used to treat behavioral and 276 
psychological symptoms of dementia (BPSD) were not detected.  277 
 278 
Nicametate Citrate, a vasodilator, was also negatively associated with incident AD. This may be 279 
in line with the literature showing effects of vasodilators on increasing cognitive function and 280 
reducing the risk of vascular dementia, although the exact mechanism remains unclear 30,31. 281 
Further research is required.  282 
  283 
Limitations 284 
One of the limitations of this study is that diagnose of AD in our EHR is not clinically 285 
ascertained. This is inevitable in nation-wide administrative data. Nevertheless, some aspects 286 
may worth noting. Firstly, we confirmed the comparable prediction outcomes using definitions of 287 
incident AD, that is, “probable AD” based on AD disease codes and “definite AD” based on both 288 
AD disease codes and anti-dementia medication, separately. Secondly, in South Korea, every 289 
elder with age 60 years old is required to have complementary dementia screening supported 290 
by the National Health Insurance Service at public healthcare centers, where individuals that 291 
high-risk for dementia get referred to physicians for further clinical examination. This healthcare 292 
system may help reduce false negative cases. These aspects may alleviate potential concerns 293 
of the validity of AD diagnoses in terms of false positive and negative cases. Lastly, the health 294 
insurance system and policies unique to Korea support the reliability of the AD diagnoses. In 295 




Korea, the Health Insurance Review and Assessment Service (HIRA) of NHIS reviews and 296 
supervises the medical claims of drugs to treat ad. For example, HIRA requires the following 297 
conditions to consider the insurance coverage of dementia medication: for donepezil and 298 
rivastigmine patches, MMSE (Mini-Mental State Examination) =< 26 and CDR (Clinical 299 
Dementia Rating) = 1~3 or GDS (Global Deterioration Scale)= 3~7; for galantamine and 300 
rivastigmine capsules, MMSE = 10 ~ 26 and CDR = 1~2 or GDS = 3~5; for memantine, MMSE 301 
=< 20 and CDR = 2~3 or GDS = 4~7. Furthermore, these medications can be only refilled when 302 
the patients meet the same criteria on follow-up neurocognitive tests every 12 months 303 
(Supplementary Figure 2). Thus, it is highly likely that individuals with records of receiving 304 
dementia medication meet strong diagnostic criteria.  305 
 306 
Another limitation of this study is that generalizability of our findings to ethnicities other than 307 




In sum, this study presents the first data in predicting future incident AD using data-driven 312 
machine learning based on large-scale EHR. Our results lend support to the development of 313 
EHR-based AD risk prediction that may enable better selection of individuals at risk for AD in 314 
clinical trials or early detection in clinical settings. 315 
316 
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Table 1. Sample characteristics 400 
 Definite AD  Probable AD Non-AD  
Number 614 2,026 38,710 
Income 6.00 (5.73-6.27) 5.90 (5.87-5.93) 6.02 (5.87-6.17) 
Age 80.67 (80.2-
81.1) 







*Based on the 0-year prediction model. 
 401 
402 




Table 2. Performance of predictive models trained on EHR.  403 
Definite AD (AD codes and dementia prescription) 







0 yr RF 614/38,710 0.887 0.687 0.737 
1 yr SVM 672/38,967 0.781 0.380 0.475 
2 yr SVM 640/38,605 0.739 0.281 0.400 
3 yr SVM 605/29,983 0.686 0.227 0.291 
4 yr RF 491/14,196 0.662 0.000 0.151 
Probable AD (AD codes) 
  







0 yr RF 2,026/38,710 0.805 0.240 0.456 
1 yr RF 2,049/38,967 0.730 0.170 0.338 
2 yr LR 1,892/38,605 0.645 0.136 0.301 
3 yr LR 1,697/29,983 0.575 0.085 0.253 
4 yr RF 1,412/14,196 0.602 0.020 0.018 
*best classifiers based on AUC. **closest values with sensitivity or specificity set to 90%  
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Table 4. Top ten features and weights from logistic regression (0-yr prediction).   409 




demography age 0.689 
health 
checkup  
urine protein 0.303 
medication Zotepine (antipsychotic drug) 0.303 
medication Nicametate Citrate (vasodilator) -0.297 
disease code other degenerative disorders of nervous system 
in diseases classified elsewhere 
-0.292 
disease code disorders of external ear in diseases classified 
elsewhere 
-0.274 
medication Tolfenamic acid   200mg (pain killer) -0.266 
disease code adult respiratory distress syndrome -0.259 
medication Eperisone Hydrochloride (antispasmodic drug) 0.255 
410 




Figure 1. Consort Diagram. 411 
  412 
413 




Figure 2. Performance of machine learning models in predicting incident AD. Receiver-414 
Operating Characteristic plots are shown for 0,1,2,3,4-year prediction. Incident AD was defined 415 
based on ICD-10 AD codes and anti-dementia medication for AD, “Definite AD”, or based on AD 416 
codes only, “Probable AD”. 417 
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Supplementary Materials 420 
Supplementary Figure 1. For the years investigated in this study, the Korean NHIS covered 421 





Supplementary Figure 2. Medical insurance system dementia medication in Korea. 427 
  428 




Supplementary Table1. Sociodemographic and Health Profile Variables Use in 429 
The Model. 430 
Variables Type of variable Explanation 
Age continuous In years 
Sex binary 0: Female; 1 : Male 






Body mass index continuous Weight(kg) / (Height*Height)(m2) 
Systolic blood pressure continuous 
mmHg 
Below 60mmHg or Above 400mmHg : 
Treated as null 
Diastolic blood pressure continuous 
mmHg 
Below 30mmHg or Above 250mmHg : 
Treated as null 
Fasting glucose continuous 
mg/dL 
Below 25mg/dL or Above 999mg/dL : 
Treated as null 
Hemoglobin NUM(3) 
Measured from 2009 
g/dL 
Above 25.0g/dL : Treated as null ~ 
Urine protein 
ordinal Measured from 2009 
1 : negative (-) 
2 : weak positive (±) 
3 : positive (1+) 
4 : positive (2+) 
5 : positive (3+) 
6 : positive (4+) 
Serum creatinine continuous mg/dL 
Serum AST continuous U/L 
Serum ALT continuous U/L 
r-GTP continuous U/L 
Family history of liver disease binary 
1 : no 
2 : yes 
Family history of hypertension binary 
Family history of stroke binary 
Family history of cardiac disease binary 
Family history of diabetes mellitus binary 
Family history of cancer binary 
Smoking status continuous 
1 : Never smoked 
2 : Not current smoker but smoked in 
the past 
3 : Current smoker 
Total smoking period ordinal 
1 : below 5 years 
2 : 5-9 years 
3 : 10-19 years 
4 : 20-29 years 
5 : over 30 years 
Current daily amount of smoking ordinal 
1 : 1~ 12 cigarettes 
2: 13-24 cigarettes 
3 : 25~48 cigarettes 
4 : over 49 cigarrettes 
Frequency of drinking alcohol ordinal 
1 : almost none 
2 : 2~3 per month 
3: 1~2 per week 
4 : 3~4 per week 
5 : almost everyday 
Amount of alcohol intake in one day ordinal 1 : below 30g of alcohol 




2 : below 60g of alcohol 
3 : below 90g of alcohol 
4 : over 120g of alcohol 
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